Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. 2. Juni 2012 Bartlett, J.M.S., Bloom, K.J., Piper, T., Lawton, T.J., van de Velde, C.J.H., Ross, D.T., Ring, B.Z., Seitz, R.S., Beck, R.A., Hasenburg, A., Kieback, D., Putter, H., Markopoulos, C., Dirix, L., Seynaeve, C., Rea, D., 2012. J Clin Oncol 30, 4477–4484. doi:10.1200/JCO.2012.42.8896 Abstract Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO). Overkamp, F., Steffens, C., Abenhardt, W., Lerchenmüller, C., Nusch, A., Göhler, T., Groschek, M., Hegewisch-Becker, S., Marschner, N., Rösel, S., Salat, C., Decker, T., 2011. Weiterlesen Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. Bossart, M., Becker, M., Hadji, P., Kieback, D.G., Hasenburg, A., 2012. Anticancer Res 32, 3933–3938. Abstract… Weiterlesen